Appili Therapeutics

Notch Therapeutics, founded in 2018 and based in Toronto, is pioneering the development of advanced T cell therapies through its innovative UNiTCell, derived from induced pluripotent stem cells (iPSCs). This off-the-shelf solution aims to address key challenges in adoptive cell therapy, providing a cost-effective and accessible option for a broader range of patients. The company's approach focuses on creating uniform and consistent T cell therapies that can be delivered at the time of diagnosis, enhancing patient experience and treatment accessibility. Notch's proprietary manufacturing methods enable the production of potent and persistent cell therapies, demonstrating robust tumor control and significant potential for improving outcomes in cancer treatment. Generated from the website

Canada's #1 Cord Blood Program

Telo Genomics Corp, based in Toronto, ON, specializes in advanced prognostic and diagnostic applications that leverage proprietary technology to enhance the treatment of diseases, particularly cancer and neurodegenerative disorders. Their innovative TeloView platform quantifies genomic instability by analyzing the three-dimensional structure and spatial organization of telomeres, providing critical insights into disease aggressiveness and treatment responses. The company offers a range of products targeting multiple myeloma, including tools for predicting relapse in newly diagnosed patients and assessing minimal residual disease post-transplant. Telo Genomics is committed to improving patient outcomes through clinically validated tests and ongoing collaborations with leading medical institutions. Generated from the website